Ozempic and Victoza are separate prescription diabetes products within the GLP-1 receptor agonist class. Ozempic contains semaglutide; Victoza contains liraglutide. Their well-known injectable forms differ in routine—weekly for Ozempic injection and daily for Victoza—and that distinction is only one part of selecting an appropriate labeled treatment.
The 30-week SUSTAIN 10 clinical trial directly compared weekly semaglutide injection with daily liraglutide in adults with type 2 diabetes receiving oral antidiabetic therapy. It reported group-average HbA1c and body-weight outcomes under studied regimens, but did not establish a personal switching schedule or compare every current presentation. For the wider brand details, see the Ozempic product guide.
Purchasing questions also involve a market change: FDA-approved liraglutide generics referencing Victoza now exist, yet an approval alone does not confirm stock at a chosen pharmacy. This page distinguishes clinical evidence from the separate Victoza brand buying guide and generic fulfillment checks.
Ozempic and Victoza have U.S. type 2 diabetes labels. Wegovy and Saxenda are separate semaglutide and liraglutide brand families used in obesity contexts, with different labeling and evidence. A reader who compares Ozempic against Victoza should not import an obesity trial into a diabetes prescribing choice.
Product form matters as well: the comparison of weekly and daily injections does not mean oral Ozempic tablets share every indication or regimen of the pen. The distinct Wegovy versus Saxenda comparison addresses weight-management brands rather than repeating the diabetes discussion here.
In SUSTAIN 10, 577 adults with type 2 diabetes on one to three oral glucose-lowering medicines were randomized to semaglutide 1.0 mg injected weekly or liraglutide 1.2 mg injected daily for 30 weeks. Mean HbA1c reduction was 1.7 versus 1.0 percentage points and weight reduction was 5.8 versus 1.9 kg in the respective trial arms.
The studied liraglutide dose and background treatment matter when interpreting these averages. The trial also observed gastrointestinal adverse events and discontinuations, so a more favorable average efficacy endpoint should not be recast as universal tolerability or the correct treatment for every patient.
This side-by-side matrix concerns diabetes-labeled semaglutide versus liraglutide, not the obesity-branded Wegovy–Saxenda question. The 30-week SUSTAIN 10 trial studied weekly injectable semaglutide 1 mg and daily injectable liraglutide 1.2 mg in 577 adults on one to three oral glucose-lowering medicines. Its mean glucose and weight results should be read alongside the observed gastrointestinal adverse events and withdrawals; a better average outcome is not a patient-specific selection rule.
For buyers, an important asymmetry is that FDA-approved liraglutide generics referencing Victoza exist, whereas an advertised “generic Ozempic” needs separate U.S. approval verification. Determine the precise injection and substitution permitted by the prescription before comparing generic tiers, brand costs or pharmacy supply.
| Practical question | Ozempic | Victoza |
|---|---|---|
| Active ingredient | Semaglutide | Liraglutide |
| Familiar injection schedule | Once weekly | Once daily |
| U.S. label identity | Diabetes brand with separate injection and tablet forms | Diabetes-brand daily injection |
| Direct comparative evidence | Semaglutide weekly arm in SUSTAIN 10 | Liraglutide daily arm in SUSTAIN 10 |
| Generic considerations | Do not infer an approved Ozempic generic | FDA-approved generics referencing Victoza exist |
A weekly injection and a daily injection impose different refill and administration routines, but the simplicity of a schedule is a preference consideration, not a standalone clinical indication. Correct injection technique and storage must follow each product’s specific label and instructions for use.
Do not transfer a liraglutide milligram amount to semaglutide, assume equivalent pens or use unverified online conversion charts. A new product may require a new prescription and clinician-directed initiation plan.
The FDA announced the first generic referencing Victoza on December 23, 2024. That matters to shoppers who see the ingredient liraglutide instead of the brand name, but it does not make a generic liraglutide product an Ozempic generic or establish that every generic can replace obesity-branded Saxenda.
For product-specific identification and legitimate substitution questions, see generic liraglutide access. Pharmacy availability, plan preference and whether a generic corresponds to the exact prescribed reference product require present-day checks.
SUSTAIN 10 assessed a specific adult diabetes population, two injection regimens and defined outcomes. It did not answer every question about oral semaglutide, long-term kidney outcomes, differing pediatric populations or product shortages. Trial superiority at a measured endpoint cannot override an individual contraindication.
A clinician may consider prior cardiovascular disease, glycemic goals, other diabetes medicines and practical administration factors. The diabetes alternatives hub gives context for other classes without claiming these products are interchangeable.
Both drug labels include serious warnings involving thyroid C-cell tumors and restrictions for personal or family history of medullary thyroid carcinoma or MEN2. Review gastrointestinal risks, pancreatitis warnings and the possibility of hypoglycemia when used with other glucose-lowering agents.
Potential kidney issues related to dehydration and other warning details should be reviewed against current labeling with a clinician. Do not buy a replacement merely because a pharmacy quotes a lower amount.
A valid prescription should identify the intended product and formulation; the dispensing pharmacist can clarify permissible generic substitution under applicable laws and the prescription instructions. A search result that simply says liraglutide may not establish its reference product or intended indication.
A buyer can ask for manufacturer, NDC where appropriate, package quantity, pharmacy license and current stock confirmation before paying. Treat sale listings without prescription checks as warning signs.
Insurers can distinguish a branded medicine from an FDA-approved generic and apply different tiers or prior-authorization rules. The retail amount, insurer copay, manufacturer support and dispensing fees are distinct concepts that should not be collapsed into a single price.
Use the semaglutide pricing guide for cross-brand cost methodology and request a dated quote for the actual prescribed item. No universal availability or discount should be inferred from regulatory approval.
An approved liraglutide generic may change purchasing options but does not retroactively alter the SUSTAIN 10 study design. A brand name may also remain searchable long after local dispensing terms change; availability and insurance acceptance still need checking.
If the brand is hard to obtain, discuss the legitimate options through clinician evaluation and prescription steps. Do not convert one ingredient to another using an online chart.
Separate age eligibility in diabetes-label products from the adult population enrolled in SUSTAIN 10. Trial results in adults cannot automatically be generalized to children or adolescents, even where a product has a separate pediatric indication.
Use verified U.S. product labeling and the liraglutide label for the prescribed presentation. Age, indication and clinician supervision are more important than a simplistic class ranking.
This review used SUSTAIN 10’s studied injection doses and the product-specific U.S. diabetes labeling available as of October 19, 2026. It does not compare oral Ozempic with Victoza, imply a dose conversion, or transfer Saxenda’s weight-management indication to Victoza. FDA approval of a Victoza-referencing generic is a regulatory fact and not a live inventory report.
This independent reference site neither prescribes liraglutide nor supplies semaglutide. Any compensated referral will need a clear disclosure beside the outbound link; a purchasing relationship does not influence which clinical label, comparator trial or generic application a reader should verify.
No. Victoza contains liraglutide; Ozempic contains semaglutide.
They share liraglutide as an ingredient but have separate brand labeling, doses and indications. The prescribed product matters.
No. There are U.S. Ozempic injection and separate oral-tablet presentations with different instructions.
It studied weekly injectable semaglutide 1.0 mg versus daily injectable liraglutide 1.2 mg over 30 weeks in adults with type 2 diabetes.
No. Published averages describe study arms and cannot predict an individual response or the most appropriate medication.
Yes. FDA announced the first generic referencing Victoza in December 2024. Approval does not guarantee local inventory.
A clinician must evaluate the change and prescribe an appropriate product. Doses and routes cannot be converted by a shopping guide.
Their approved labels have serious thyroid C-cell tumor warnings and associated contraindications. Review product-specific safety information with the prescriber.
No. Formularies, pharmacy participation, prescribed quantity and program eligibility determine actual patient expenses.